Compare RXRX & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RXRX | FSK |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2021 | 2008 |
| Metric | RXRX | FSK |
|---|---|---|
| Price | $3.11 | $10.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | $7.50 | ★ $13.94 |
| AVG Volume (30 Days) | ★ 11.6M | 4.1M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 19.88% |
| EPS Growth | ★ 14.79 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $74,681,000.00 | N/A |
| Revenue This Year | $12.11 | N/A |
| Revenue Next Year | $82.52 | N/A |
| P/E Ratio | ★ N/A | $252.88 |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.80 | $9.72 |
| 52 Week High | $7.18 | $22.68 |
| Indicator | RXRX | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 45.29 |
| Support Level | $2.98 | $10.28 |
| Resistance Level | $5.03 | $10.56 |
| Average True Range (ATR) | 0.17 | 0.35 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 42.57 | 91.62 |
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.